Target
Aspartyl/asparaginyl beta-hydroxylase
Ligand
BDBM21447
Substrate
n/a
Meas. Tech.
ChEMBL_2018813 (CHEMBL4672391)
IC50
2990±n/a nM
Citation
 Brewitz, LTumber, AZhang, XSchofield, CJ Small-molecule active pharmaceutical ingredients of approved cancer therapeutics inhibit human aspartate/asparagine-?-hydroxylase. Bioorg Med Chem 28:0 (2020) [PubMed]  Article 
Target
Name:
Aspartyl/asparaginyl beta-hydroxylase
Synonyms:
1.14.11.16 | ASP beta-hydroxylase | ASPH | ASPH_HUMAN | Aspartate beta-hydroxylase | Aspartyl/asparaginyl beta-hydroxylase | BAH | Peptide-aspartate beta-dioxygenase
Type:
PROTEIN
Mol. Mass.:
85823.27
Organism:
Homo sapiens
Description:
ChEMBL_120098
Residue:
758
Sequence:
MAQRKNAKSSGNSSSSGSGSGSTSAGSSSPGARRETKHGGHKNGRKGGLSGTSFFTWFMVIALLGVWTSVAVVWFDLVDYEEVLGKLGIYDADGDGDFDVDDAKVLLGLKERSTSEPAVPPEEAEPHTEPEEQVPVEAEPQNIEDEAKEQIQSLLHEMVHAEHVEGEDLQQEDGPTGEPQQEDDEFLMATDVDDRFETLEPEVSHEETEHSYHVEETVSQDCNQDMEEMMSEQENPDSSEPVVEDERLHHDTDDVTYQVYEEQAVYEPLENEGIEITEVTAPPEDNPVEDSQVIVEEVSIFPVEEQQEVPPETNRKTDDPEQKAKVKKKKPKLLNKFDKTIKAELDAAEKLRKRGKIEEAVNAFKELVRKYPQSPRARYGKAQCEDDLAEKRRSNEVLRGAIETYQEVASLPDVPADLLKLSLKRRSDRQQFLGHMRGSLLTLQRLVQLFPNDTSLKNDLGVGYLLIGDNDNAKKVYEEVLSVTPNDGFAKVHYGFILKAQNKIAESIPYLKEGIESGDPGTDDGRFYFHLGDAMQRVGNKEAYKWYELGHKRGHFASVWQRSLYNVNGLKAQPWWTPKETGYTELVKSLERNWKLIRDEGLAVMDKAKGLFLPEDENLREKGDWSQFTLWQQGRRNENACKGAPKTCTLLEKFPETTGCRRGQIKYSIMHPGTHVWPHTGPTNCRLRMHLGLVIPKEGCKIRCANETKTWEEGKVLIFDDSFEHEVWQDASSFRLIFIVDVWHPELTPQQRRSLPAI
  
Inhibitor
Name:
BDBM21447
Synonyms:
4-(4-{[2-(4-chlorophenyl)phenyl]methyl}piperazin-1-yl)-N-[(4-{[(2R)-4-(dimethylamino)-1-(phenylsulfanyl)butan-2-yl]amino}-3-nitrobenzene)sulfonyl]benzamide | ABT-737 | CHEMBL376408 | N-Benylpiperazine derivative, 2 | US11760752, Compound ABT-737 | US9125913, ABT-737
Type:
Small organic molecule
Emp. Form.:
C42H45ClN6O5S2
Mol. Mass.:
813.427
SMILES:
CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1 |r|
Structure:
Search PDB for entries with ligand similarity: